Immune-Related Circulating MiR-125b-5p and MiR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients After Tumor Resection

Overview

Journal Appl Sci (Basel)

Date 2021 Sep 6

PMID 34484811

Citations 4

Authors

Eveline E Vietsch

Ivana Peran

Mustafa Suker

Thierry P P van den Bosch

Fleur van der Sijde

Johan M Kros

Casper H J van Eijck

Anton Wellstein

Affiliations

Soon will be listed here.

Abstract

Clinical follow-up aided by changes in the expression of circulating microRNAs (miRs) may improve prognostication of pancreatic ductal adenocarcinoma (PDAC) patients. Changes in 179 circulating miRs due to cancer progression in the transgenic ; ; (KPC) animal model of PDAC were analyzed for serum miRs that are altered in metastatic disease. In addition, expression levels of 250 miRs were profiled before and after pancreaticoduodenectomy in the serum of two patients with resectable PDAC with different progression free survival (PFS) and analyzed for changes indicative of PDAC recurrence after resection. Three miRs that were upregulated ≥3-fold in progressive PDAC in both mice and patients were selected for validation in 26 additional PDAC patients before and after resection. We found that high serum miR-125b-5p and miR-99a-5p levels after resection are significantly associated with shorter PFS (HR 1.34 and HR 1.73 respectively). In situ hybridization for miR detection in the paired resected human PDAC tissues showed that miR-125b-5p and miR-99a-5p are highly expressed in inflammatory cells in the tumor stroma, located in clusters of CD79A expressing cells of the B-lymphocyte lineage. In conclusion, we found that circulating miR-125b-5p and miR-99a-5p are potential immune-cell related prognostic biomarkers in PDAC patients after surgery.

Citing Articles

miRNAs in pancreatic cancer progression and metastasis.

Mok E, Chitty J, Cox T Clin Exp Metastasis. 2024; 41(3):163-186.

PMID: 38240887 PMC: 11213741. DOI: 10.1007/s10585-023-10256-0.

Clinical Value of Circulating miRNA in Diagnosis, Prognosis, Screening and Monitoring Therapy of Pancreatic Ductal Adenocarcinoma-A Review of the Literature.

Wnuk J, Strzelczyk J, Gisterek I Int J Mol Sci. 2023; 24(6).

PMID: 36982210 PMC: 10049684. DOI: 10.3390/ijms24065113.

Obese Mouse Fat Cell-derived Extracellular Vesicles Transport miR-99a-5p to Mitigate the Proliferation and Migration of Non-small Cell Lung Cancer Cells.

Zhai S, Li X, Lin T Comb Chem High Throughput Screen. 2023; 27(2):214-226.

PMID: 36927435 DOI: 10.2174/1386207326666230316103604.

Distinct Response of Circulating microRNAs to the Treatment of Pancreatic Cancer Xenografts with FGFR and ALK Kinase Inhibitors.

Peran I, Vietsch E, Yan G, Riegel A, Wellstein A Cancers (Basel). 2022; 14(6).

PMID: 35326668 PMC: 8945909. DOI: 10.3390/cancers14061517.

References

Andersen C, Jensen J, Orntoft T . Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004; 64(15):5245-50. DOI: 10.1158/0008-5472.CAN-04-0496. View

Conlon K, Klimstra D, Brennan M . Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996; 223(3):273-9. PMC: 1235115. DOI: 10.1097/00000658-199603000-00007. View

Pritchard C, Kroh E, Wood B, Arroyo J, Dougherty K, Miyaji M . Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2011; 5(3):492-497. PMC: 4186243. DOI: 10.1158/1940-6207.CAPR-11-0370. View

Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen L . The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol. 2014; 8(4):819-29. PMC: 5528532. DOI: 10.1016/j.molonc.2014.02.009. View

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

Pecqueux M, Liebetrau I, Werft W, Dienemann H, Muley T, Pfannschmidt J . A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. Int J Mol Sci. 2016; 17(10). PMC: 5085780. DOI: 10.3390/ijms17101755. View

Malik N, Sansom O, Michie A . The role of mTOR-mediated signals during haemopoiesis and lineage commitment. Biochem Soc Trans. 2018; 46(5):1313-1324. PMC: 6195642. DOI: 10.1042/BST20180141. View

Lu L, Liston A . MicroRNA in the immune system, microRNA as an immune system. Immunology. 2009; 127(3):291-8. PMC: 2712098. DOI: 10.1111/j.1365-2567.2009.03092.x. View

Cao Z, Liu C, Xu J, You L, Wang C, Lou W . Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Oncotarget. 2016; 7(27):41575-41583. PMC: 5173079. DOI: 10.18632/oncotarget.9491. View

10.

Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y . Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Gene. 2018; 673:181-193. DOI: 10.1016/j.gene.2018.06.037. View

11.

Zhang C, Zhang C, Ma M, Dai D . Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients. World J Gastroenterol. 2018; 24(11):1206-1215. PMC: 5859223. DOI: 10.3748/wjg.v24.i11.1206. View

12.

Jopling C . Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012; 9(2):137-42. PMC: 3346312. DOI: 10.4161/rna.18827. View

13.

Ganepola G, Rutledge J, Suman P, Yiengpruksawan A, Chang D . Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014; 6(1):22-33. PMC: 3936193. DOI: 10.4251/wjgo.v6.i1.22. View

14.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

15.

Haglund C, Roberts P, Kuusela P, Scheinin T, Makela O, Jalanko H . Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer. 1986; 53(2):197-202. PMC: 2001324. DOI: 10.1038/bjc.1986.35. View

16.

Xu J, Cao Z, Liu W, You L, Zhou L, Wang C . Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Ann Surg. 2015; 263(6):1173-9. DOI: 10.1097/SLA.0000000000001345. View

17.

Shivapurkar N, Vietsch E, Carney E, Isaacs C, Wellstein A . Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib. Clin Transl Med. 2017; 6(1):37. PMC: 5628092. DOI: 10.1186/s40169-017-0169-y. View

18.

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F . A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6):R64. PMC: 2718498. DOI: 10.1186/gb-2009-10-6-r64. View

19.

van Roessel S, Mackay T, Tol J, van Delden O, van Lienden K, Nio C . Impact of expanding indications on surgical and oncological outcome in 1434 consecutive pancreatoduodenectomies. HPB (Oxford). 2019; 21(7):865-875. DOI: 10.1016/j.hpb.2018.10.020. View

20.

Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C . Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016; 44(8):3865-77. PMC: 4856985. DOI: 10.1093/nar/gkw116. View